MKI67 and neoplasm: Given the low Ki-67 index, indicative of a slow-growing, low-grade tumor with limited expected benefit from systemic chemotherapy, she was initiated on subcutaneous octreotide (Sandostatin) 100 mcg twice daily for symptom control and tumor stabilization.